FDA Launches Global Reliance Disclosure Program, Expanding NME and BLA
FDA's GRDP expands to all NMEs and BLAs in January 2027, requiring a 10-day post-approval request window and confirmed foreign-market submissions.


Regulatory affairs teams at companies holding New Molecular Entity NDAs and 351(a) Biologics License Applications face a concrete operational deadline: the FDA's newly announced Global Reliance Disclosure Program (GRDP) expands to all novel drugs and biologics in January 2027, requiring updated SOPs and a defined foreign-market strategy before that window opens.
The GRDP, launched October 30, 2026, enables the FDA to share minimally redacted approval packages, including full scientific and regulatory assessments, directly with applicants, who may then submit them to foreign regulatory authorities in support of marketing applications. The mechanism allows overseas health authorities to rely on FDA review decisions without conducting independent evaluations, while retaining sovereign decision-making authority. The program launched initially with a PEPFAR tentative approval for lenacapavir, indicated for HIV prevention and treatment.
Participation carries a strict procedural requirement: applicants must request their minimally redacted action package within 10 calendar days of approval and confirm the package is being submitted to a foreign authority for a marketing application. Requests outside that purpose are routed through standard Freedom of Information Act (FOIA) channels and will not receive expedited processing under the GRDP. Eligible applicants will receive participation details directly in FDA approval letters.
The January 2027 expansion to NMEs and BLAs substantially broadens the program's scope beyond the current PEPFAR-only eligibility, which excludes tentatively approved ANDA products. The FDA has also signaled a separate pathway launching in early 2027 to expedite minimally redacted package requests for drugs and biologics already approved and on the U.S. market, extending the program's reach to the existing portfolio.
For QA directors and regulatory leads, the compliance read centers on documentation readiness: the 10-day request window leaves no margin for internal approval workflows that are not already aligned to the GRDP trigger. Teams managing multi-regional launch strategies will need to identify target foreign markets before approval, not after, to meet the confirmation requirement within the prescribed timeframe.
The January 2027 expansion date sets a measurable checkpoint against which regulatory operations teams can benchmark SOP revision and foreign-market prioritization work.
Source: FDA press announcement via FDA.gov What's New: Drugs RSS Feed, November 17, 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
EktaH Advances NKS-3 Obesity Drug into Phase IIa After Securing €2.4 Million Funding

Innate Pharma Achieves Phase 1 Milestone for IPH4502 ADC with Linker Stability Signal

Discussion